Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Study Objectives:
1. The primary objective is to characterize the pharmacokinetics of a single oral
administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis
of episodic migraine with or without aura.
2. The secondary objectives are to determine:
1. The safety and tolerability of Cambia from a single dose
2. Three-month safety evaluation of Cambia in outpatient usage in this population